INTRODUCTION
Enhancers confer spatiotemporal specificity to gene expression and orchestrate gene expression patterns in response to environmental and/or developmental stimuli (Lam et al., 2014) . Enhancers account for the majority of transcription factor binding sites in the genome and have a characteristic chromatin structure (Heinz et al., 2015) . The number of potential enhancer elements greatly exceeds the number of coding regions; however, most are maintained in a silent or poised state until an activating signal is received (Rada-Iglesias et al., 2011) . Upon activation, binding of cell type or temporal-specific transcription factors (TFs) to cognate DNA motifs recruits transcription coactivators, such as histone acetyltransferases CREB binding protein (CBP) and p300 and RNA polymerase II (PolII) (Creyghton et al., 2010; Li et al., 2013) . This results in two hallmarks of active enhancers: the production of bi-directional non-coding RNA transcripts known as enhancer RNAs (eRNAs) (Hah et al., 2011; Kim et al., 2010; Wang et al., 2011; Ørom et al., 2010) and elevated histone 3 lysine 27 acetylation (H3K27ac) (Creyghton et al., 2010) .
Increasing evidence points to a direct role for eRNAs in enhancer function (Kim and Shiekhattar, 2015) . eRNAs regulate looping between enhancers and promoters through recruitment of cohesin (Hsieh et al., 2014; Li et al., 2013) , increase chromatin accessibility (Mousavi et al., 2013) , and aid the recruitment of mediator to promoters (Lai et al., 2013) . Consistently, depletion of eRNAs affects transcription from enhancer-associated genes (Kim et al., 2010; Lai et al., 2013; Li et al., 2013; Melo et al., 2013; Mousavi et al., 2013) . At poised genes, eRNAs promote release of paused PolII into the gene body (Schaukowitch et al., 2014) .
Several non-coding RNAs (ncRNAs) interact with chromatinmodifying enzymes and modulate enzymatic function (Cifuentes-Rojas et al., 2014; Di Ruscio et al., 2013; Kaneko et al., 2014a Kaneko et al., , 2014b Kaneko et al., , 2013 Wongtrakoongate et al., 2015; Yang et al., 2014) . Binding of RNA to Polycomb repressive complex 2 (PRC2) decreases its methyltransferase activity and recruitment to promoters (Beltran et al., 2016; Cifuentes-Rojas et al., 2014; Kaneko et al., 2013 Kaneko et al., , 2014a Kaneko et al., , 2014b . ncRNA transcribed proximal to the C/EBPA locus interacts with DNA methyltransferase 1 (DNMT1) to block DNA methylation at the promoter (Di Ruscio et al., 2013) . A key question is whether eRNAs play a similar role in modulating chromatin at enhancers. Indeed, eRNA transcripts do not direct methylation changes at enhancers upon activation, which result from active transcription by PolII (Kaikkonen et al., 2013) .
Elevated H3K27ac is another hallmark of active enhancers, produced by CBP and p300 (Jin et al., 2011; Tie et al., 2009) . CBP/p300 bind a vast array of TFs through transactivation domains (TADs), acting as a transcription network ''hub' ' (Bedford et al., 2010; Wang et al., 2013) . The broad interactome results in nearly universal recruitment of CBP and p300 to enhancers, such that CBP/p300 occupancy is a key feature (Creyghton et al., 2010) and identifies enhancers genome-wide (May et al., 2011) . The enzymatic activity of CBP and p300 is localized in their catalytic histone acetyltransferase (HAT) domain and targets both histones and numerous TF substrates, including p53 and PolII (Barlev et al., 2001; Jin et al., 2011; Schrö der et al., 2013; Tie et al., 2009; Wang et al., 2008a) . Acetylation of PolII by CBP promotes PolII release into the gene body (Schrö der et al., 2013) . H3K27ac correlates with regions of active transcription genome-wide (Tie et al., 2009; Wang et al., 2008b) , and CBP-mediated acetylation can directly stimulate transcription by improving TF recruitment efficiency and promoter escape of PolII (Stasevich et al., 2014) . Targeting the p300-HAT domain alone to enhancers using de-activated Cas9 nuclease (dCas9) and enhancer-specific guide RNAs (gRNAs) increases expression of enhancer-associated genes (Hilton et al., 2015) . Thus, p300-mediated acetylation is sufficient for gene activation at endogenous enhancers and loci.
RNA could potentially impact the function of CBP and p300. Transcription of the antisense ncRNA khps1 from the promoter of the proto-oncogene SPHK1 helps to recruit p300 to the SPHK1 promoter (Postepska-Igielska et al., 2015) . Moreover, stable depletion of eRNA transcribed from an enhancer for chorionic gonadotropin alpha (Cga) decreased H3K27ac (Pnueli et al., 2015) . A key open question is whether there is a direct mechanistic connection between eRNA and CBP function at regulatory elements.
Here, we demonstrate a direct interaction between CBP and RNA, including a large population of eRNAs. In vivo crosslinking and sequencing identified a subset of CBP-bound eRNAs associated with genes requiring CBP for their transcription. eRNA binding directly stimulates acetyltransferase activity of CBP in vitro, modulating H3K27ac levels. In cells, eRNA transcripts modulate their local chromatin environment, regulating H3K27ac to promote gene expression.
RESULTS

CBP Interacts with RNA In Vivo
The ability of CBP to interact directly with RNA in cells is untested, although some evidence suggests interactions (Castello et al., 2012; Hendrickson et al., 2016; Postepska-Igielska et al., 2015) . To validate the association of CBP with RNA without crosslinking, we carried out an RNA immunoprecipitation (RIP) experiment under native conditions from mouse embryonic fibroblasts (MEFs) and found that CBP IP co-purifies a population of bound RNA (Figures 1A and S1A) . To determine whether immunoprecipitated RNAs were interacting directly with CBP rather than indirectly through another CBP-bound protein, we used photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) (Figure 1B) (Hafner et al., 2010; Huppertz et al., 2014) . We observed PAR-CLIP signal corresponding to CBP that was dependent on labeling of the bound RNA with 4-thiouridine (4-SU) . We note that, similar to other PAR-CLIP results (Hafner et al., 2010; Kaneko et al., 2013 Kaneko et al., , 2014a , cross-linked CBP-RNA complexes migrated in a less defined band due to crosslinking with heterogeneous RNAs. Labeling was sensitive to RNase treatment, confirming that the material crosslinked to CBP was RNA ( Figures 1E, 1F , and S1F-S1H).
CBP-Bound RNAs Arise from Sites of CBP Binding
To investigate how CBP interacts with RNA across the genome, we sequenced CBP PAR-CLIP libraries from two biological replicates. To control for background RNA binding events (Friedersdorf and Keene, 2014), we also prepared libraries for nuclearlocalized and Flag epitope-tagged GFP (nGFP) and for the DNA binding domain of the yeast TF Gal4p (Gal4-DBD) (two replicates each) (Figures 2A and S2A) . Statistically enriched RNA regions were identified on individual and pooled replicate datasets using PARalyzer v.1.1, which takes advantage of the T-to-C transitions caused by photo-crosslinking to identify interaction sites . CBP PAR-CLIP read densities from each replicate were well correlated in the RNA regions called by PARalyzer on the separate replicates (Pearson's coefficient = 0.93; Pearson's coefficient = 0.95 for common regions between replicates) (Figure S2B) . Having confirmed the reproducibility of our CBP PAR-CLIP sequencing experiments, we pooled the replicates to identify a consensus set of CBP-bound RNA regions for downstream analyses. This resulted in 11,041 CBP-bound RNAs (CBP-RNAs) with a median size of 19 bp (Figure S2C ). There were 2,367 bound RNAs in common between Gal4-DBD and nGFP controls, 2,922 between CBP and Gal4-DBD, and 2,020 between CBP and nGFP ( Figures S2D-S2F ); in total, $71% (7,835) of CBP-RNAs did not appear in the background controls, suggesting that these represent specific signal from CBP-associated RNAs ( Figure S2G ; Table S1 ). We did not detect RNA-dependent interactions between CBP and other eRNA interacting proteins, such as Mediator (Lai et al., 2013) or negative elongation factor (NELF) (Schaukowitch et al., 2014) under native (Figure S2H) or PAR-CLIP ( Figure S2I ) conditions. Using published ChIP-seq data Sun et al., 2011) , we found no difference in Med-1 signal at CBPRNAs compared to background RNAs (Figure S2J ), although NELF signal was enriched at CBP-RNAs, suggesting active transcription at these regions (Figure S2J ). Thus, we were unable to detect co-binding of CBP and other eRNA interacting proteins to the same RNAs.
We compared the distribution of CBP PAR-CLIP signal with published CBP chromatin immunoprecipitation sequencing (ChIP-seq) and global run-on sequencing (GROseq) (Meng et al., 2014) datasets in MEFs. Genome browser views of bound RNA regions and corresponding reads, such as at a target enhancer upstream of Tet2 (Figures 2B and 2C) , revealed increased PAR-CLIP read density. In many locations such as the Tet2 enhancer, CBP PAR-CLIP reads mapped to regions of chromatin showing nascent transcription (by GROseq) and CBP occupancy (by ChIP-seq; Figures 2B  and 2C ). The majority of CBP-RNAs (73%) were found in intergenic (47%) or intronic regions (26%) of the genome similar to CBP itself (72%; 43% intergenic, 29% intronic) ( Figure 2D ). The remaining CBP-RNAs arise from exons (23%) and very few (4%) from promoters ( Figure 2D ). As only 4% of CBP chromatin binding sites are at exons, we examined the distribution at exons and promoters in greater detail. The high level of exonic CBPRNAs relative to CBP binding appears to result from increased false-positives due to the high transcription and stability of exons. First, actual PAR-CLIP reads are enriched at promoters and distal sites, compared to exons (Figure S2K ). Second, the enrichment for CBP-RNAs at exons was relatively low, especially when compared to high transcription at exons (Figures S2K and S2L) . Third, the transcription start site (TSS) 1-kb window used to define promoters limited the number of CBP-RNAs assigned to promoters. Therefore, the distribution of CBP-RNAs reflects patterns of CBP chromatin binding genome-wide.
Compared to RNAs bound in the negative control libraries, CBP-RNAs were enriched for CBP ChIP-seq signal (Figure 2E) and were slightly more likely to comprise accessible chromatin ( Figure 2F ). CBP-RNAs had more nascent transcription by GROseq ( Figure 2G ) and were enriched for more stable RNA transcripts in total RNA sequencing (RNA-seq) data ( Figure S2M ). We then compared levels of nascent transcription (GROseq) to stable RNA transcripts (total RNA-seq) at CBP-RNAs. The CBP-RNAs most enriched for GROseq reads also displayed high-read density in total RNA-seq data ( Figure S2N ) and vice versa ( Figure S2O ). Nevertheless, CBP-RNAs with low enrichment in total RNA-seq still demonstrated transcription by GROseq ( Figure S2O , bottom deciles). Consistent with this, CBP-RNAs arising from stable transcripts at exons were strongly enriched for total RNA-seq reads, but GROseq reads were strongly enriched at promoters and distal regions (Figure S2P ). This reflects the ability of GROseq to detect the often-unstable, nascent RNA transcripts at these locations, where most CBPRNAs arise (Figure 2D) , and suggests that CBP-RNAs contain an abundant population of nascent RNAs. There was an inverse correlation between peak-to-peak distance of CBP ChIP-seq and PAR-CLIP signal when considering intersecting CBP and CBP-RNAs ( Figure S2Q ), with a higher Spearman co-efficient at short distances. Importantly, there was a consistent and more robust correlation with CBP ChIP signal for CBP-RNAs than for Gal4-DBD or nGFP control RNAs ( Figure S2Q ). Taken together, these data demonstrate that CBP-RNAs localize at sites with nascent RNA transcription and within regions of chromatin bound by CBP.
CBP Binds to eRNAs
As CBP-RNAs originated from transcribed chromatin regions occupied by CBP, two hallmarks of enhancers, we sought to determine whether CBP-RNAs corresponded to eRNAs. To account for the typical length of eRNAs, we focused on 1,138 locations where the center of the CBP-RNAs was less than 3.5 kb from the nearest CBP peak and where CBP-ChIP-seq and PAR-CLIP signal were strongly correlated ( Figure S2Q ) (De Santa et al., 2010; Kim et al., 2010) . These CBP-RNAs close to CBP-ChIP-seq peaks showed strong enrichment for PAR-CLIP reads ( Figure S3A ) compared to CBP-RNAs arising further from a CBP peak. They were also enriched for CBP ChIP-seq and GROseq reads ( Figures S3B and S3C ), suggesting a positive relationship between PAR-CLIP signal and levels of CBP recruitment and transcription. To account for differences in CBP chromatin binding genome-wide ( Figure 2D ), we divided CBP peaks proximal to CBP-RNAs into promoter (TSS 1 kb, 133 peaks, 13.5%), exonic (256 peaks, 26.2%), and distal (intergenic/intronic, 587 peaks 60.1%) subgroups (Figure 3A and S3D) . Sites with the highest enrichment for PAR-CLIP reads corresponded to regions most enriched for CBP in all three groups; the highest levels of CBP are found at the most enriched PAR-CLIP sites in promoter and distal regions-classical regions of CBP binding (Figure S3E) . Locations with highest CBP binding (Figure S2F) and GROseq signal (Figure S3G) promoters and distal sites compared to exons (Figures S3L and S3M) . The abundance of CBP-RNAs corresponded to the level of CBP chromatin binding at actively transcribed regions. Therefore, RNA binding to CBP appears to be locus specific: CBPRNAs arise from transcribed regions at locations where CBP binds to chromatin. The large number of distal CBP-RNAs ( Figure 2D ) reflects the prevalence of CBP binding to enhancers in distal regions of the genome . Distal CBP-RNA sites display bidirectional RNA transcription, enriched CBP occupancy, more accessible chromatin (increased DNase I hypersensitivity) and elevated levels of H3K27ac ( Figure 3B ). Furthermore, distal sites have higher H3K27ac ( Figure S3N ) and nascent transcription by GROseq ( Figure S3O ) compared to non-RNA interacting control CBP binding sites. Moreover, distal CBP-RNAs are enriched for H3K4me1 and depleted for H3K4me3. CBP therefore appears to interact with eRNAs at distal enhancers (referred to hereafter as CBP-eRNA). We note that, within CBP-eRNA loci, distal regions of strong GROseq signal are associated with elevated H3K4me3 (Figure 3A ), reflecting more active transcription at these sites. We asked whether CBP-eRNAs had a chromatin signature of active enhancers, characterized by elevated H3K27ac. Of 766 CBPRNAs intersecting H3K4me1, 532 (69.5%) also overlapped H3K27ac peaks ( Figures 3E and S3Q-S3S ). However, of 533 distal CBP-eRNAs that intersect H3K4me1, 459 (86.1%) overlapped H3K27ac and thus displayed an active enhancer signature.
Enhancers often regulate expression of adjacent genes (Kim et al., 2010; Lai et al., 2013; Li et al., 2013; Melo et al., 2013; Mousavi et al., 2013) . Gene ontology (GO) analysis revealed that the genes nearest to CBP-eRNAs are significantly enriched for transcription regulators, including TFs, mediator subunits, and epigenetic regulators ( Figure S3S ; Table S2 ). Furthermore, motif analysis identified binding sites for known CBP-interacting TFs (Table S3) (Bedford et al., 2010) . The amount of CBP and p300 bound at promoters and enhancers is a poor predictor of the CBP/p300 requirement for expression of proximal genes . Genes associated with CBP-eRNA (Table  S4) tend to be downregulated upon CBP knockdown relative to genes not associated with CBP-eRNA ( Figure S3T ) (data from published microarray ). We used RTqPCR to examine the effect of CBP knockdown (control in Figure S3U ) on newly identified eRNA transcripts and associated mRNA expression at a subset of genes ( Figures 3G and 3H ). The majority of tested mRNAs (8/9; 89%) were downregulated upon CBP knockdown (Figure 3H) , and four of eight (50%) of the corresponding eRNAs were also decreased ( Figure 3G ), indicating that these selected genes are direct targets of CBP. Overall, our data support the conclusion that distal CBP-eRNA regions represent a subset of active enhancers where eRNAs bind to CBP, and whose associated genes require CBP activity for expression.
In Vitro Reconstitution of CBP RNA Binding To investigate RNA binding to predicted RNA binding regions (RBRs) within CBP (BindN (Wang and Brown, 2006) , Figures  4A and S4A ), we purified full-length CBP (CBP-FL) from Sf9 cells (Figure S4B, left panel) . Using an RNA pull-down (Bonasio et al., 2014) with in-vitro-transcribed RNA probes corresponding to eRNA-Klf6 ( Figure 4B ) and eRNA-Med13l (Figure 4C ), we observed RNA interactions with CBP-FL (but not in control experiments), suggesting that CBP directly binds to RNA ( Figures  4C, 4D , S4C, and S4D).
RNA binding predictions for CBP ( Figure 4A ) suggested a highly basic region (residues 1561-1620) within the core HAT domain might contain the observed RNA binding activity. This region shares >90% identity with p300 and comprises basic residues that are evolutionarily conserved and disordered (Delvecchio et al., 2013; Liu et al., 2008; Wang et al., 2008a) . To investigate the predicted RBR in the HAT domain, CBP (CBP-HAT wt ), which contains all functional domains necessary for HAT activity (Delvecchio et al., 2013) , was purified from bacteria ( Figure S4B , right panel). RNA pull-down using sequences from nascent eRNAs (e-Klf6, e-Tet2, e-Klf4), processed lncRNAs (HOTAIR 1-300 , Gas5, Meg3), and exonic RNAs (Id-1 [exon 1], Bbs2 [exon 1], Klf2 [exon 3]) (Figures 4E, 4F, demonstrated that CBP-HAT wt in isolation could bind to multiple different RNA sequences. However, we noted that binding to eRNA sequences was more consistent than binding to lncRNAs and exons ( Figure S4G ). Thus, CBP-HAT wt recapitulated the interaction of CBP-FL with RNA ( Figures 4B-4D , S4C, and S4D) and displayed a general rather than sequence-specific RNA binding activity in vitro. As CBP-RNAs were enriched at sites of CBP chromatin binding (Figure 2 ), this supports a genomic locus-specific binding model, where RNAs transcribed proximal to CBP can bind to the RBR independent of RNA sequence.
Next, we used RNA electrophoretic mobility shift assays (EMSAs) to evaluate RNA binding of CBP-HAT wt to radiolabeled eRNA target sequences (Table S5 ). All sequences displayed a robust mobility shift when titrated with CBP-HAT wt (Figures 4G, 4H, S4H, and S4I) . Moreover, binding to labeled eRNA-Mdm2 ( Figure 4I ) was outcompeted by identical unlabeled eRNA. Importantly, single strand (ss) and double strand (ds) DNA with (B) and (C) . n = 3. (E) In vitro pull-down of eRNA-Klf6 s . RNA input and protein fractions in Figure S4E . (F) Quantification of RNA pull-down data in (B) and (C) . n = 3. the same sequence could not compete with the CBP-eRNA interactions ( Figure 4J ), demonstrating that CBP-HAT wt binds specifically to RNA in vitro. The predicted RBR in the HAT domain (Q1559-K1608) (Figure S4A ) forms a highly basic disordered loop, which was proteolytically cleaved in X-ray crystallographic structures of the p300 HAT domain (Delvecchio et al., 2013; Liu et al., 2008) . Binding of eRNA-Klf6 to CBP in pull-downs ( Figures 4E, 4F , and S4E) and eRNA-Mdm2 in EMSA ( Figure 4K ) was severely decreased when Q1559-K1608 was deleted (CBP-HAT delta-loop ) ( Figure S4J ). To test whether the charge of the loop was important for RNA binding, we mutated basic residues within the loop to acidic residues not predicted to interact with RNA (CBP-HAT mutant-loop ) ( Figure S4J ). We maintained lysine residues that are known targets for CBP-mediated auto-acetylation regulating CBP-HAT activity and positively charged residues important for lysine targeting by CBP (Liu et al., 2008; Thompson et al., 2001 Thompson et al., , 2004 . Notably, the acetylation state of the RBR loop was important for RNA binding, as CBP-HAT wt only exhibited detectable RNA binding when co-expressed with lysine deacetylase ySir2 (Figure S4K) , suggesting interplay between auto-acetylation of the RBR loop and RNA binding. In contrast, CBP-HAT mutant-loop displayed severe defects in RNA binding when co-expressed with ySir2, both in RNA pull-downs with eRNA-Klf6 ( Figures  4E, 4F , and S4E) and in RNA EMSAs using radiolabeled eRNA probes ( Figure 4L ), confirming the importance of basic residues within the RBR for RNA binding to the CBP-HAT domain.
We next asked whether CBP-eRNAs could interact with the identified RBR in CBP using PAR-CLIP in cells. We quantified binding of CBP-eRNA to full-length CBP wt , CBP delta-loop , or CBP mutant-loop in cells by PAR-CLIP followed by RT-qPCR (Figure 4M , control in Figure S4L ). CBP delta-loop and CBP mutant-loop showed drastically reduced binding to CBP-eRNAs compared to CBP wt (Figure 4M) , suggesting that the identified RBR within the regulatory loop is the predominant but not the only site of interaction for CBP with eRNAs. Overall, the in vitro RNA binding experiments demonstrate that CBP can directly associate with RNA. Moreover, a specific RNA-binding sequence located within a basic loop that is part of the HAT domain, constitutes a previously unrecognized RBR within CBP. The binding data suggest that CBP can bind to RNA in a locus-specific manner, independent of RNA sequence; thus, a bias toward eRNAs is observed due to the high recruitment of CBP to enhancer regions where it interacts with nascent eRNA transcripts.
CBP Acetyltransferase Activity Is Stimulated by RNA Binding
Having defined an RBR within the HAT domain of CBP, we next investigated whether RNA binding affects the HAT activity of CBP, using a radioactive filter-binding assay (Figure S5A) . Increasing concentrations of two different eRNAs, eRNA-Ccnd1 and eRNA-Klf6, stimulated CBP HAT activity (Figure 5A) . Both eRNAs stimulated activity in a dose-dependent manner, but the magnitude and pattern of activity differed slightly between eRNA species. There was no equivalent stimulation when titrating control Ccnd1 single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA) ( Figure 5A ). Stimulation was independent of RNA sequence but required RNA binding to the RBR: HOTAIR 1-300 and Id-1 (exon 1), which bound robustly to CBP-HAT wt ( Figure S5B )-stimulated activity, but Meg3, which bound poorly, did not ( Figures S5B and S5C ). Importantly, HAT activity did not increase in CBP deleted for the RBR (CBP-HAT delta-loop , Figure 5B ). Thus, RNA binding to the RBR within the HAT domain of CBP stimulates HAT activity.
Next, we determined whether RNA binding increases CBPdependent histone modifications. CBP acetylates distinct lysine residues, including H3K27ac and H3K18ac on histone H3 and H4K5ac on histone H4 in vitro (Henry et al., 2013) . We repeated the HAT assay using reconstituted recombinant nucleosomes ( Figure S5D ) and assayed by western blot. The level of both H3K27ac and H4K5ac increased as eRNA concentration was titrated (Figures 5C-5E and S5E-S5G), confirming that increased activity with RNA translates to higher H3K27ac ( Figure 5C ) and H4K5ac ( Figure 5D ) in vitro. Stimulation was independent of RNA sequence; eRNA-YY1 ( Figure 5E ), eRNA-Mdm2, eRNACcnd1, and lncRNA-HOTAIR 1-300 all stimulated both H3K27ac and H4K5ac ( Figures S5E-S5G ), although the different sequences generated different profiles of acetylation. The effect was also observed for recombinant H3 in isolation (Figure S5H , quantified in Figure S5I ). The dose response is U shaped; at high molar ratios of RNA to CBP-HAT, there was a drop in H3K27ac (Figures 5C and S5I) and H4K5ac ( Figure 5D ), which could result from CBP interactions with RNA outside of the primary CBP-RBR at high RNA concentrations. Consistent with this hypothesis, the activity of CBP-HAT delta-loop also decreased at high RNA concentrations ( Figure 5B); we note that most eRNAs have low abundance in different systems (Kim et al., 2010; Lam et al., 2013; Li et al., 2013) . When the experiment was repeated with recombinant human MYST protein Males Absent on the First (hMOF), there was no stimulation of H4K16ac, the major acetylation site of hMOF ( Figure S5J ). MYST-type acetyltransferases such as hMOF, although also regulated by acetylation, do not contain a CBP/p300-like RBR (Wang et al., 2008a) .
RNA binding to the HAT domain of CBP through the identified RBR therefore stimulates acetyltransferase activity in an RNA concentration-dependent manner, generating increased levels of H3K27ac and H4K5ac in vitro.
Mechanism of RNA Stimulation of Acetyltransferase Activity CBP/p300 are regulated by a basic activation loop that blocks substrate binding to the active site (Liu et al., 2008; Thompson et al., 2004; Wang et al., 2008a) . The loop is displaced by acetylation, which permits substrate binding. In steady-state HAT (K and L) assays, this causes a decrease in the concentration of substrate needed to reach half maximum acetylation rate (K M ) (Thompson et al., 2004) . Remarkably, the location of the CBP/p300 activation loop largely overlaps the position of the RBR within the HAT domain ( Figures 4A and S4A ). We therefore tested whether eRNA binding to the RBR could stimulate the HAT activity of CBP through a similar reduction of auto-inhibition. We adapted our radioactive filter binding assay to evaluate the steady-state kinetic mechanism of stimulation of CBP activity by eRNA (Bowers et al., 2010) (Figures 5F and 5G; kinetic parameters are summarized in Figure S5K and a model for activation in Figure 5J ). Our calculated value of K M(H3-1-21) for CBP-HAT wt (K M(H3-1-21) = 44.55 ± 3.99 mM) ( Figure 5F ) closely matches previous values for recombinant p300 HAT domain (K M(H4-15) = 40 ± 8 mM) (Thompson et al., 2004) . Consistent with our model, addition of 10 nM eRNA-Mdm2 decreased the K M(H3-1-21) of CBP-HAT wt from 44.55 ± 3.99 to 26.42 ± 3.55 mM ( Figure 5F ). We note that while 10 nM eRNA also slightly decreased the K cat ( Figure 5F ), the specificity constant K cat /K M was increased, reflecting an increase in catalysis ( Figure 5H ). Hence, in common with acetylation of the activation loop, the stimulation of CBP HAT activity by eRNA binding is due to its increased affinity for histone substrate rather than to an alteration of the catalytic mechanism.
To confirm this mechanism, CBP-HAT mutant-loop , which does not bind to eRNA ( Figure 4N ), displayed no change in the K M with 10 nM eRNA ( Figure 5G ). Indeed, the K M of CBP-HAT mutant-loop in the absence of eRNA was already decreased (K M(H3-1-21) = 27.30 ± 5.65 mM) compared to CBP-HAT wt (K M(H3-1-21) = 44.55 ± 3.99 mM) ( Figure S5K ). This indicates that mutation of basic residues to acidic residues within the loop is sufficient to displace the loop from the active site and thus mimic the effect of eRNA binding. Inclusion of eRNA, which does not interact with the mutant loop, has no further effect on the K M , and consequently there is no increase in K cat /K M(H3-1-21) (Figures 5I and S5K) . Importantly, K cat with 10 nM RNA was similar for both CBP-HAT mutant-loop and CBP-HAT wt , which suggested that the decrease in K cat observed in both cases was independent of eRNA binding to the RBR (cf. Figures 5F and 5G, values in Figure S5K ). However, as 10 nM RNA did not change the K M of CBP-HAT mutant-loop , the specificity constant K cat /K M was slightly decreased (Figures 5I and S5K) . These data indicate that eRNA binding to the RBR within the activation loop results in its displacement from the active site of CBP. This allows improved substrate binding, decreases the K M in the presence of eRNA, and thus enhances the HAT activity of CBP (see model in Figure 5J ).
eRNAs Modulate the Acetyltransferase Activity of CBP In Vivo Our data demonstrate that CBP binds to RNAs transcribed close to CBP binding sites such as at the YY1 enhancer ( Figure 6A) ; recruitment of CBP to active enhancers results in binding to eRNAs, and that eRNA binding to the HAT domain of CBP stimulates its acetyltransferase activity.
We next asked whether depletion of CBP-eRNAs in cells reduces histone acetylation in a locus-specific manner. RT-qPCR following transfection of antisense-oligonucleotides (ASO) targeting eRNA-YY1 ( Figures 6A and S6A ), compared to GFP ASO control, revealed specific depletion of the targeted eRNA-YY1 and reduction of the adjacent coding mRNA (Figures 6B and S6E) . Importantly, eRNA and mRNA at non-targeted Ccnd1 loci ( Figure 6B , bottom panel; Figure S6E ) was not significantly reduced upon depletion of eRNA-YY1. We note that eRNA-YY1 depletion also slightly affects expression of Tet2 mRNA, likely indirectly through depletion of YY1 protein, as the Tet2 promoter contains a YY1 motif (TRANSFAC [Matys et al., 2006] ). Similarly, ASO that depleted eRNA-Ccnd1 ( Figure S6B ) reduced levels of eRNA and adjacent coding mRNA at Ccnd1 but not at non-targeted YY1 and Tet2 loci ( Figures 6C and S6E ).
We depleted eRNA-YY1 and found a similar reduction of H3K27ac ( Figure 6D ) and H3K18ac ( Figure 6E ), whereas there was no significant change in acetylation at the Ccnd1 control enhancer and promoter loci (Figures 6D and 6E, bottom panel) or at Tet2 control loci (Figures S6F and S6G, bottom panel) . There was also no change in CBP occupancy at enhancer or promoter regions (Figure 6F) . Similarly, depletion of eRNA-Ccnd1 decreased H3K27ac (Figure 6G ) and H3K18ac (Figure 6H ) at the Ccnd1 enhancer and promoter but produced no change in acetylation at the YY1 enhancer and promoter (Figures 6G and 6H, bottom panels) and no change in CBP occupancy (Figure 6I) . Acetylation was also reduced at the Tet2 enhancer and promoter upon depletion of eRNA-Tet2 ( Figures S6H and S6I) , with no alteration in CBP binding (Figure S6J ) or acetylation at YY1 control loci. (We note that this did not lead to decreased Tet2 mRNA, consistent with our previous observation that loss of CBP did not reduce Tet2 mRNA levels in Figure 3H .) Importantly, for all three examples, eRNA depletion caused decreased acetylation specifically at the target enhancer and promoter, but not at control enhancer and promoter loci.
Our findings lead to a model (Figure 7) where CBP binding to specific eRNA transcripts regulates CBP acetyltransferase activity in cis. This results in a local increase in CBP-dependent histone acetylation at the same enhancer and target promoter regions. eRNA binding therefore contributes to enhancer-specific patterns of histone acetylation at regulatory regions.
DISCUSSION
Our results provide direct evidence of RNA binding to CBP in cells. We show that CBP interacts in a locus-specific manner with RNAs transcribed proximal to sites of CBP chromatin binding. By interacting with a CBP/p300-specific RBR located within its catalytic HAT domain, RNA stimulates the HAT activity of CBP. This observation has particular importance at enhancers, where CBP binding, histone acetylation, and eRNA production are interconnected. Localizing acetyltransferase activity to enhancers is sufficient to promote transcription of associated genes (Hilton et al., 2015) . Our findings link these events in a mechanistic manner: eRNA binding to CBP in cis stimulates the localized acetyltransferase activity at enhancers, increasing H3K27ac and H3K18ac at the enhancer and, importantly, at the target promoter, thereby promoting gene expression. Nevertheless, further work is needed to fully elucidate the role of CBP dependent acetylation at enhancers in regulating gene expression. The mechanism of regulation by activation loop is unique to CBP/p300 among acetyltransferases (Wang et al., 2008a) . Remarkably, we show that this same motif renders the HAT activity of CBP sensitive to RNA (Figures 5F and 5G). Our observation that acetylation was important for RNA binding ( Figure S4K ) suggests a possible interplay between RNA binding and auto- acetylation of the loop region. CBP is therefore a further example of a chromatin-modifying enzyme whose activity can be regulated by direct binding of ncRNAs, similar to PRC2 (CifuentesRojas et al., 2014; Kaneko et al., 2014b) and DNMT1 (Di Ruscio et al., 2013) . However, for CBP, RNA binding contributes to an active chromatin profile through stimulation of CBP HAT activity.
Our data suggest that CBP could bind to many RNA sequences with broadly similar affinities (Figure 4 ). Binding could therefore be promiscuous, similar to PRC2 (Cifuentes-Rojas et al., 2014; Davidovich et al., 2015; Kaneko et al., 2013 Kaneko et al., , 2014a . RNA binding to CBP also appears to be locus specific: CBP binds to RNAs where it is recruited to chromatin. CBP activity at promoters could also be regulated by RNA, although the prevalence of enhancer-bound CBP results in a strong bias toward eRNA binding. Promiscuous, locus-specific RNA binding has obvious benefits for a transcriptional co-activator such as CBP with a broad genome-wide binding profile, allowing RNAs to stimulate local CBP activity regardless of their sequence. Moreover, RNAs could potentially generate locusspecific activity and acetylation profiles, thus enabling fine-tuning of target gene expression. This model enables a de-coupling of CBP/p300 recruitment from histone acetylation and transcriptional output, helping to explain why CBP/p300 recruitment is a poor predictor of gene activation (Bedford et al., 2010; . Consistently, depletion of CBP-eRNAs decreased H3K27ac and H3K18ac specifically at associated promoters and modulated gene expression ( Figures 6F, 6G , 6I, and 6J).
In conclusion, we show that RNAs transcribed proximal to CBP binding sites directly interact with CBP in cis. Binding to the RBR within the catalytic HAT domain of CBP-a region critical for regulating HAT activity-allows substrate to bind more easily and thereby stimulates the HAT activity of CBP. At active enhancers, CBP binds to eRNAs leading to elevated histone acetylation and increased transcription of target genes (Figure 7 ). In this model, CBP-mediated histone acetylation can be regulated independently from CBP recruitment and allows enhancer-and gene-specific tuning of acetylation. By stimulating CBP activity, RNA binding can generate a tailored chromatin environment at target genes to fine-tune transcriptional output.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture wt Mouse Embryonic Fibroblasts (MEFs) (ATCC, CRL-2991) were cultured in complete DMEM (10% FBS, 1% Penn-strep) at 37 C in 5% CO 2 . CBP/p300 flox/flox MEFs (kindly provided by Paul Brindle ) were cultured in complete DMEM (10% FBS, 0% Penn-strep) at 37 C in 5% CO 2 . GP2-293 cells were cultured in complete DMEM (10% FBS, 1% Penn-strep) at 37 C in 5% CO 2 .
Bacterial cultures
For expression of recombinant proteins in bacteria, Rosetta 2 DE3 cells (EMDMillipore) were grown in Luria Broth (LB) of 2YT broth. Cells were grown at 37 C with shaking at 225rpm until OD 600nm = 0.4-0.6. Expression was induced with 1mM IPTG. Expression time and temperature were optimized for individual constructs (details in Protein expression and purification). Cells were harvested by centrifugation at 4800rpm for 15 min.
Sf9 cultures
For expression of full-length CBP, Sf9 insect cells (ThermoFisher) were grown in serum-free Sf900-III medium (ThermoFisher). Suspension cultures (1-2e 6 cells/ml) were infected with high-titer passage 2 (P2) virus stock at a multiplicity of infection (MOI) of 1. Cells were harvested after 24h. Table S5 Antisense oligonucleotides (ASO) IDT See 
METHOD DETAILS
RNA immunoprecipitation
Native RNA immunoprecipitation (Native RIP) Native RIP experiments were carried out from nuclear extracts. Cells were harvested and washed with PBS + 1 mM EDTA, then with Buffer A (10 mM Tris pH 7.9 4 C, 1.5 mM MgCl2, 10 mM KCl, supplemented with Complete EDTA free protease inhibitor (Roche)). Cells were lysed by incubating with Lysis Buffer (Buffer A + 0.2% IGEPAL CA-630) for 10 min on ice. Nuclei were isolated by centrifugation at 2,500xg for 5 min and lysed in Buffer C (20 mM Tris pH 7.9 4 C, 25% glycerol, 400 mM NaCl, 1.5 mM MgCl2, 10 mM EDTA, 0.4 u/ml murine RNase inhibitor (NEB), Complete EDTA free protease inhibitor (Roche) for 30 min at 4 C. Lysates were cleared by centrifugation at 20,000xg for 30 min. Protein-RNA complexes were immunoprecipitated by incubating with a depleting amount of antibody for 3h at 4 C in RIP buffer (20 mM Tris pH 7.9 4 C, 200 mM KCl, 0.05% IGEPAL CA-630, 10 mM EDTA). Immunocomplexes were recovered with Protein A dynabeads (ThermoFisher) blocked with BSA for 30 min. Beads were washed twice with RIP Wash Buffer (RIP Buffer + 0.05% NP40, 1mM MgCl2) and contaminating DNA was removed by incubating with 2.5U Turbo DNase I (ThermoFisher) for 10 min at 21 C. 20% of resuspended beads were retained for western blot. RNA was purified using Trizol (ThermoFisher) and isopropanol precipitation. A second incubation with 2.5U Turbo DNase I at 37 C for 30 min ensured no DNA contamination. Immunoprecipitated RNA was resolved on a 6% denaturing TBE Urea gel and imaged with SYBR gold. PAR-CLIP For Photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP), Cells were incubated for 16h with 150uM 4-thiouridine (4-SU). Plates were washed with PBS before cells were cross-linked using 150mJ/cm2 365nM UV light with a Stratalinker UV crosslinker (Stratagene). All subsequent stages of PAR-CLIP were carried out immediately to prevent degradation of cross-linked CBP. Cells were harvested by scraping in PBS supplemented with 1mM EDTA and lysed by incubating for 10 min on ice with CLIP lysis buffer A (20mM HEPES KOH pH7.9, 150mM KCl, 5mM EDTA, 2% EMPIGEN, 0.1% Na-deoxycholate, 0.5% N-lauroylsarcosine, 0.1% SDS, 2mM DTT) supplemented with Complete EDTA free protease inhibitor (Roche), Murine RNase inhibitor (NEB), Turbo DNase I (ThermoFisher) and sonicated for 2x 30 s cycles in a bioruptor (Diagenode). Cell lysate was cleared by centrifugation at 20000xg for 30 min. The cleared cell lysates were subjected to an initial partial RNase digestion step using RNase/T1 cocktail (4000x) (ThermoFisher) for 5 min at 21 C to improve immunoprecipitation efficiency (Friedersdorf and Keene, 2014; Hafner et al., 2010; Huppertz et al., 2014) . Immunopreciptations were carried out using a depleting amount of anti-CBP antibody (Santa Cruz, sc-583) for 2 hr at 4 C. Lysates were then subjected to a second, more stringent RNase treatment using RNase A/T1 cocktail (10x) for 15 min at 37 C before recovering immunocomplexes for 30 min with BSA blocked Protein A dynabeads (ThermoFisher). The digestion with higher RNase concentration was important for optimizing transfer efficiency of the large (> 250KDa) CBP-RNA complexes. Beads were collected and washed twice with CLIP wash buffer (20mM Tris HCl pH 7.9 (4 C), 400mM KCl, 5mM EDTA, 0.5mM EGTA, 2% EMPIGEN, 0.7% Na-deoxycholate, 0.5% N-lauroylsarcosine, 2M Urea, 2mM DTT, protease inhibitors) then IP50 buffer (20mM Tris HCl pH 7.9 (4 C), 50mM KCl, 0.2mM EDTA, 10% Glycerol, 2mM DTT), before resuspending in 1x Turbo DNase buffer. CLIP wash buffer contains 2M Urea, which was important for removing non-specific RNA binding while retaining immunoprecipitated protein-RNA complexes. Contaminating DNA was removed by incubation with 2.5U Turbo DNase I for 30 min at 37 C. Beads were washed with CLIP wash buffer and IP50 buffer. Cross-linked RNA complexes were dephosphorylated by incubating with Recombinant Shrimp Alkaline Phosphatase (rSAP, NEB) for 15 min at 37 C, washing with Phosphatase wash buffer (20mM Tris HCl pH 7.9 (4 C), 400mM KCl, 10mM EDTA, 10mM EGTA, 0.05% IGEPAL CA-630, 2mM DTT) then T4-PNK buffer (50mM Tris HCl pH 7.5 (at room temperature (RT)), 50mM NaCl, 10mM MgCl2, 5mM DTT). Protein-RNA complexes were then labeled by incubating with 5U T4 PNK (NEB) with 10uCi g-32 P-ATP for 15 min at 37 C, then for 5 min with 100uM unlabelled ATP. Labeled material was washed again with CLIP wash buffer and IP50 before denaturing with 4x LDS loading buffer (ThermoFisher) and resolving on a 3%-8% TrisAcetate gel. For RNase titration experiments, following labeling, samples were incubated with different RNase concentrations for 15 min at 37 C. Gels were transferred to 0.2uM PVDF membrane for 12h at 40V, then exposed to autoradiography screens or X-ray film for 12-24h to image labeled RNA complexes. Autoradiography screens were imaged using a Typhoon Phosphorimager (GE Healthcare). For western blot analysis, PAR-CLIP membranes were probed with anti-CBP antibody (Abcam, ab2832) for 16h).
Sequencing libraries for PAR-CLIP seq
For sequencing experiments, labeled CBP-RNA bands (or control bands) were excised from the membrane and eluted by incubating with RNA elution buffer (50mM HEPES pH7.0, 50mM NaCl, 1mM EDTA, 2mM CaCl 2 , 1% SDS) and Proteinase K (4mg/ml, NEB) for 30 min at 37 C, then for 30 min at 55 C with RNA elution buffer + 3.5M Urea and Proteinase K. Proteinase K was pre-incubated for 15 min at 37 C before use to remove contaminating RNase. RNA was then purified using acidic phenol:chloroform (ThermoFisher) and ethanol precipitation.
Sequencing libraries for PAR-CLIP experiments were prepared using NEB next small RNA library set for Illumina sequencing (New England Biolabs) according to manufacturers instructions. Libraries were checked for quality by bioanalyzer before and after size selection by Pippin prep (Sage science) and were 50bp single-end sequenced on an Illumina NextSeq 500.
Bioinformatic analyses PAR-CLIP analysis
Following de-multiplexing, sequences corresponding to illumina adaptors were removed using Cutadapt v1.7.1 (Martin, 2011) and reads greater than 15nt in length were retained (cutadapt -a AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC -e 0.1 -m Cloning of CBP (full-length) For expression of recombinant proteins, full-length CBP was cloned into pFastBAC HTA (ThermoFisher), modified with an in-frame N-terminal 1x Flag tag and 6xHisTag. All PCR reactions were carried out using PfuUltra II Fusion HS DNA Polymerase (Agilent). CBP was cloned in two parts using single copy Xba1 site at position 3294-3299; CBP 1-3299 was cloned into BamHI/XbaI sites in pFastBac HTA using primers (Fwd: DB_PCR_1; Rvs: DB_PCR_2); CBP 3294-7326 was then cloned into XbaI/HindIII sites in the pFastBAC HTA-CBP 1-3299 construct using primers (Fwd: DB_PCR_3; Rvs: DB_PCR_4). Cloning re-forms the native XbaI site in full length CBP (Plasmid: pFB:CBP-FL wt ); all constructs were checked for correct frame by sequencing through restriction sites.
For expression of full-length CBP in mammalian cell lines, CBP was initially cloned into pAcGFP-C1 (Clontech) modified to remove the SacI restriction site. CBP was cloned in two separate reactions: First, a silent SalI restriction site was introduced into FL-CBP at position 3464 using primers (Fwd: DB_PCR_5; Rvs: DB_PCR_6). CBP 1-3464 was cloned in frame with an N-terminal GFP tag using HindIII/SalI sites in the pAcGFP-C1 vector using primers (Fwd: DB_PCR_7; Rvs: DB_PCR_8). CBP was cloned into pAcGFP-C1 using SalI/BamHI sites in the vector with primers (Fwd: DB_PCR_9; Rvs: DB_PCR_10). CBP 3465-7326 was sub-cloned into SalI/ BamHI sites in pAcGFP-C1-CBP 1-3464 to reconstruct FL-CBP in frame with the N-terminal GFP-tag. Cloning re-forms the silent SalI site in full length CBP; all constructs were checked for correct sequence and frame by sequencing through restriction sites. N-terminal GFP-tagged FL-CBP was sub-cloned with an additional in-frame N-terminal Flag-epitope tag into BamHI/NotI sites in the pTRE3G vector using primers (Fwd: DB_PCR_11; Rvs: DB_PCR_12). All work with viral vectors was carried out using One Shot Stbl3 E. coli (ThermoFisher) to reduce recombination of repeat sequences. Cloning of CBP-HAT wt constructs CBP 1196-1718 (CBP-HAT wt ) was cloned into BamHI/NotI sites in pGEX-4T-1 (Novagen) encoding an in-frame GST tag (plasmid: pGEX4T1:CBP-HAT wt ). To generate CBP-HAT delta-loop mutants, primers (Fwd: DB_PCR_13; Rvs: DB_PCR_14) were used to amplify CBP-HAT wt in pGEX-4T-1 in reverse directions to delete residues (aa1559-1608, 4677-4732bp) using PFu Ultra II high fidelity DNA polymerase (Agilent) (plasmid: pGEX4T1:CBP-HAT delta-loop ). For CBP-HAT mutant loop constructs, we inserted two SacI sites using silent mutations at positions 4612 and 5089 into CBP-HAT wt in pGEX-4T-1 using primers (Fwd: DB_PCR_15, Rvs: DB_PCR_16). The insert sequence coding for wild-type CBP-HAT with mutant loop residues (aa1559-1608, 4677-4732bp, lower case in sequence below) was ordered as a gBlock gene fragment (IDT) with flanking SacI sites (see Table S6 for sequence). The insert sequence was amplified by PCR, digested with SacI and ligated into SacI digested CBP-HAT wt . Inserts were checked for correct frame and orientation by sequencing (plasmid: pGEX4T1:CBP mutant-loop ).
Cloning of CBP mutant constructs
To clone full-length CBP delta-loop and CBP mutant loop into pTRE3G, constructs were generated using the same method as for CBP-HAT domain constructs (see above) in pAcGFP-C1-CBP . Mutant CBP 3465-7326 was then sub-cloned into SalI/BamHI sites in pAcGFP-C1-CBP 1-3464 to reconstruct FL-CBP in frame with the N-terminal GFP-tag. Cloning re-forms the silent SalI site in full-length CBP; all constructs were checked for correct frame by sequencing through restriction sites (plasmid: pAcGFPC1:CBP-FL wt ; pAcGFPC1:CBP-FL delta-loop ; pAcGFPC1:CBP-FL mutant-loop ). N-terminal GFP-tagged FL-CBP was sub-cloned with an additional in-frame N-terminal Flag-epitope tag into BamHI/NotI sites in the pTRE3G vector using primers (Fwd: DB_PCR_17; Rvs: DB_PCR_18) (plasmid: pTRE3G:CBP-FL wt ; pTRE3G:CBP-FL delta-loop ; pTRE3G:CBP-FL mutant-loop ). All work with viral vectors was carried out using One Shot Stbl3 E. coli (ThermoFisher) to reduce recombination of repeat sequences. Cloning of ySir2 ySir2 was cloned into pET28-b + (EMDMillipore) at EcoRI/HindIII sites using primers (Fwd: DB_PCR_19, Rvs: DB_PCR_20) (plasmid:
pET28b+:ySir2).
Protein expression and purification CBP (full length) Flag tagged full-length CBP in pFastBAC HTA was packaged into baculovirus and transfected into Sf9 cells for expression. Sf9 insect cells (ThermoFisher) were grown in serum-free Sf900-III medium (ThermoFisher). Suspension cultures (1-2e 6 cells/ml) were infected with high-titer passage 2 (P2) virus stock at a multiplicity of infection (MOI) of 1. Cells were harvested after 24h to achieve optimal expression and purity. Sf9 expression was courtesy of David Schultz and the Wistar protein expression facility. All subsequent purification stages were completed on a single day to limit degradation of purified CBP fractions. For purification of full length CBP, Sf9 cell pellets from 2L culture were re-suspended in Buffer A (20mM TrisHCl pH7.3 (RT) , 300mM NaCl, 2mM MgCl 2 , 5% Glycerol, 2mM DTT) supplemented with 0.1% NP40, 0.1mM PMSF, Complete EDTA free protease inhibitor (Roche), 1mM Benzamidine, Benzonase (5U/ml final), 1mM Na-Butyrate and lysed by sonication. Cell lysates were cleared by centrifugation (18000rpm, 45 min, 4 C) and filtered through a 0.45uM syringe filter. Cleared lysates were loaded on to a 5ml Ni-Affinity HisTrap HP column (GE healthcare) using an Akta purifier FPLC. The column was washed with Buffer A and eluted with Buffer B (Buffer A + 500mM Imidazole). Fractions corresponding to eluted protein were collected and loaded on to a gravity flow column (Biorad) packed with 3 mL Flag-M2 agarose (Sigma) and equilibrated with Buffer A. Flow through was collected and re-loaded on to packed column two more times to ensure maximum yield of purified CBP. The loaded column was washed three times with buffer A, and bound protein was eluted with 3x Flag elution buffer (Buffer A + 100ug/ml 3x Flag-peptide (Sigma)). Elution was repeated 3x to ensure maximum yield. Fractions with CBP were pooled and concentrated using a Vivaspin centrifugal concentrator (GE Healthcare) and loaded on a Superdex 200 16/60 size exclusion column equilibrated with Buffer A. Fractions containing CBP were collected and concentrated using a Vivaspin centrifugal concentrator (GE Healthcare). Protein concentration was determined using a nanodrop with extinction co-efficient and molecular weight parameters and verified by Bradford assay (Biorad). Purified protein was checked for RNase contamination using an RNase Alert lab test kit (Ambion) and dialysed into Buffer D (Buffer A + 50% glycerol + 0.2mM EDTA). Fractions corresponding to eluted protein were collected at each purification stage and checked for purity by SDS-PAGE on a 3%-8% Tris acetate gel. Purified protein was divided into single use aliquots, flash frozen in liquid nitrogen and stored at À80
C. CBP-HAT domain constructs CBP-HAT domain constructs (CBP-HAT wt , CBP-HAT mutant-loop , CBP-HAT delta1559-1608 ) in pGEX-4T-1 (Ampicillin) were expressed in Rosetta 2 DE3 cells (EMDMillipore) in Luria Broth (LB). Constructs were co-expressed with ySir2 in pET-28b + (Kanamycin); coexpression improved yield by limiting indiscriminate acetylation of host proteins and autoacetylation of expressed CBP-HAT wt domain (Thompson et al., 2004) . Co-expression with ySir2 was required for RNA binding to CBP ( Figure S4K ). Cells were grown at 37
C with shaking at 225rpm until OD 600nm = 0.4-0.6, then shifted to 22 C and induced with 1mM IPTG for 4 hr. Cells were harvested by centrifugation at 4800rpm for 15 min.
Cell pellets were lysed in GST Buffer A (20mM TrisHCl pH7.3 (RT), 300mM NaCl, 0.2mM EDTA, 1mM DTT, 5% Glycerol, 10mM NaButyrate and supplemented with Complete protease inhibitor cocktail (Roche). Cells were lysed by sonication. Cell lysates were cleared by centrifugation at 18000 rpm for 45 min at 4 C. Cell lysates were filtered with a 0.45uM syringe filter and loaded on to an equilibrated 5ml GSTrap HP column (GE Healthcare) using an Akta Purifier FPLC at 4 C (GE Healthcare). The column was washed with GST Buffer A; bound protein was eluted using a linear gradient of 0%-100% GST Buffer B (GST Buffer A + 10mM Glutathione (reduced)). Purity was determine by SDS-PAGE using a 4%-12% Bis-Tris gel run in 1x MOPS SDS buffer. Eluted fractions containing CBP-HAT constructs were pooled and concentrated using a Vivaspin centrifugal concentrator (GE healthcare). Concentrated protein was dialysed overnight into GST-Buffer D (GST Buffer A + 20% glycerol). Protein concentration was determined using a nanodrop with calculated extinction co-efficient and molecular weight parameters. Purified protein was checked for RNase contamination using an RNase Alert lab test kit (ThermoFisher). Purified protein was divided into single use aliquots, flash frozen in liquid nitrogen and stored at À80 C. Nucleosomes Recombinant human nucleosomes were reconstituted using established protocols (Lowary and Widom, 1998; Luger et al., 1999; Tanaka et al., 2004) described in detail below. Human histones in pET15-b + (EMDMillipore) were expressed in Rosetta 2 DE3 cells (EMDMillipore) in 2YT broth. Cells were resuspended in Histone buffer A (50mM TrisHCl pH8.0 (RT), 500mM NaCl, 1mM PMSF, 5% Glycerol) and lysed by sonication. Cell lysates were cleared by centrifugation at 18000 rpm for 45 min at 4 C. Cell pellets were retained and resuspended in Histone buffer B (50mM TrisHCl pH8.0 (RT), 500mM NaCl, 1mM PMSF, 5% Glycerol, 6M Urea). Supernatents were loaded on to a gravity flow column (Biorad) packed with 3ml Ni-NTA agarose (QIAGEN) and equilibrated with Histone buffer B, washed three times with Histone buffer B and eluted with Histone Elution buffer (Histone buffer B + 500mM imidazole) and checked for purity by SDS-PAGE. Purified histones were dialysed into MilliQ water + 2mM B-mercaptoethanol and lyophilized. To reconstitute histone octamers, lyophilized histones were dissolved in Unfolding buffer (7M guanidinium HCL, 20mM Tris-HCl pH7.5 (RT), 10mM DTT). Equimolar ratios of H2A, H2B, H3 and H4 were mixed and dialysed against Re-folding buffer (2M NaCl, 10mM Tris-HCl pH7.5 (RT), 1mM EDTA, 5mM B-mercaptoethanol). Trace precipitate was removed by centrifugation and the re-folded octamer was purified on a Superdex 200 16/60 size exclusion column equilibrated with Re-folding buffer. Purity and stoichiometry of the reconstituted octamer was checked by SDS-PAGE. Nucleosome core particles were then re-constituted using a 207bp Widom-601 DNA sequence (Lowary and Widom, 1998) via stepwise dialysis from 2M to 250mM KCl over a 48h period (Luger et al., 1999; Peterson, 2008) . Purity and stoichiometry was confirmed by SDS-PAGE and DNA binding to the reconstituted nucleosome was visualized by 6% Native PAGE stained with SYBR gold (Figure S5D ). RNA in vitro transcription and 32-P radio-labeling eRNA probes were designed according to the presence of nascent RNA transcripts in GROseq data and to incorporate the location of cross-linked RNA in PAR-CLIP data. No cap or poly-A tail was added. Sequences corresponding to eRNA targets (Table S5) were ordered as gBlock gene fragments (IDT) and cloned into pIDT-smart vectors digested with EcoRV (NEB) by blunt end cloning. Templates for in vitro transcription reactions were PCR amplified using PFu Ultra II high fidelity DNA polymerase (Agilent) with primers to include a T7 RNA polymerase promoter site at the 5 0 end of the sequence (Table S6 ) and confirmed to be the expected size by agarose gel electrophoresis. In vitro transcription reactions were carried out using a MAXIscript T7 RNA polymerase in vitro transcription kit (ThermoFisher) for 2 hr at 37 C. DNA templates were then removed by digestion with Turbo DNase I (ThermoFisher) for 30 min at 37 C. Transcribed RNA templates were resolved on a 6% denaturing TBE Urea gel. RNA bands were excised from the gel and eluted using RNA elution buffer (50mM BisTris pH6.7, 300mM Na-Acetate, 1% SDS, 10mM EDTA) and ethanol precipitated. Purified RNA probes were re-suspended in BTE (10mM Bis-Tris pH6.7 (RT), 1mM EDTA) and quantified by Qubit (ThermoFisher).
For end-labeling reactions, RNAs were dephosphorylated with calf intestinal alkaline phosphatase (CIP) (In a 20ul Reaction: 1-100pmol RNA, 1x CIP buffer (50mM Tris, pH 8.5, 0.1 mM EDTA, pH 8.0), 0.1U/ul CIP (NEB)) for 1 hr at 37 C followed by purification with acidic Phenol: Chloroform (ThermoFisher) and ethanol precipitation. De-phosphorylated RNA was then end labeled with T4 Polynucleotide Kinase and [g-32 P] ATP (In a 20ul Reaction: 1-100pmol RNA, 25 pmol [g-32 P]ATP (7000 Ci/mmol, 150 mCi/ml), 1x Kinase buffer 50 mM Tris, pH 7.5, 10 mM MgCl2, 5 mM DTT), 0.5 U/ml T4 PNK (NEB) for 1 hr at 37 C. Un-incorporated nucleotides were removed with a Mini Quickspin RNA column (Roche) and the labeled RNAs were gel purified from 6% denaturing TBE Urea gel as above. RNA was ethanol precipitated, re-suspended in BTE and quantified by Cerenkov counting.
Purification of ssDNA and dsDNA probes To purify ssDNA probes, target sequences were amplified by PCR from template DNA using one biotinylated and one non-biotinylated primer. PCR products were gel purified to remove unbound primers. Purified, biotinylated dsDNA probes were conjugated to streptavidin M-280 magnetic beads (ThermoFisher) in 1x Binding Wash buffer (10mM TrisHCl pH7.5, 0.5mM EDTA, 1M NaCl) then washed with 4x with 1x Binding Wash buffer. dsDNA was then denatured chemically by resuspending beads in 0.2M NaOH and incubating for 6 min at 22 C in a thermomixer. Supernatent containing ssDNA was transferred to an equal volumne of 5M Ammonium acetate pH6.8, then purified by isopropanol precipitation. ssDNA probes were then gel purified to ensure correct sizing, and checked on a denaturing 6% TBE Urea gel stained with SYBR gold. dsDNA probes were amplified by PCR from template DNA using PFu Ultra II high fidelity DNA polymerase (Agilent) and gel purified. All purified DNA probes were quantified by Qubit (ThermoFisher).
In vitro RNA binding assays In vitro pull-down RNA binding assays RNA binding assays were carried out using recombinant proteins and re-folded RNA probes. RNA probes were re-folded as above. Flag-tagged full-length CBP or GST-tagged CBP-HAT domain constructs were incubated with 20nM re-folded RNA with rotation at 4 C for 1 hr in RNA Buffer A (20mM Tris HCl pH7.4 (RT), 200mM KCl, 0.2mM EDTA, 2mM DTT, 10% Glycerol, 0.05% NP40, 10mM EDTA). Protein-RNA complexes were recovered with Glutathione agarose beads (ThermoFisher) or Flag-M2 agarose (Sigma) for 30 min at 4 C with rotation. Beads were washed three times with RIP wash buffer (RNA Buffer A + 1mM MgCl 2 ). Samples for protein analyses were resuspended in LDS sample loading buffer and resolved by SDS-PAGE. Samples for RNA analyses were purified using Trizol and resolved on a denaturing 6% TBE Urea gel stained with SYBR gold. Replicate experiments were fully independent experiments completed on different days, and included multiple independently purified protein and RNA samples. RNA electrophoretic mobility shift assay RNA electrophoretic mobility shift assays (RNA EMSAs) used established protocols.
32-P radiolabelled RNA was diluted to 20,000cpm, 20nM with unlabeled RNA in BTE. RNA was re-folded by incubating for 5 min at 95 C before snap-cooling on ice for 5 min. RNA re-folding buffer (10mM Bis-Tris pH6.7, 50mM KCl, 10mM MgCl 2 ; 1x final) was added to RNA on ice. For re-folding, RNA was transferred to an ice-cold metal block and allowed to fold by warming to room temperature ($21 C) for 30 min. Binding reactions were assembled in RNase free, low adhesion microcentrifuge tubes. Reactions contained 1x RNA binding buffer (20mM Tris HCl pH7.4, 100mM KCl, 1mM EDTA, 1% glycerol, 0.05% NP40, 2mM DTT, 0.5mM ZnCl 2 , 0.4U/ul murine RNase inhibitor (NEB)), 0.1mg/ml BSA (NEB), 0.1mg/ml yeast tRNA (Sigma). Unless otherwise stated, 2000cpm (2nM) of re-folded RNA (Or BTE + 1x RNA re-folding buffer) was added to each reaction. For competition binding experiments, the desired concentration of un-labeled RNA, ssDNA or dsDNA was added along with labeled RNA. Binding reactions were started by adding the required concentration of CBP-HAT domain construct and allowed to proceed for 30 min at 4 C. Reactions were loaded immediately on a 6% Native polyacrylamide gel (29:1 Acrylamide:Bis-acrylamide) pre-run for 1h at 100V in 0.5X TBE, and run for 2h at 100V. Gels were vacuum dried for 60 min at 80 C and exposed to autoradiography screen or X-ray film for 12h before imaging with a Typhoon phosphorimager (GE Healthcare). Replicate experiments were fully independent experiments completed on different days, and included independently purified protein and RNA samples. Densitometric analysis was carried out in FIJI; binding curves were calculated using non-linear regression in R.
Histone acetyltransferase assays Steady state kinetic characterization and analysis Steady state HAT assays were carried out using protocols adapted from (Bowers et al., 2010; Henry et al., 2013; Thompson et al., 2004) . RNA probes were refolded as above. Reactions were assembled in RNase Free, low adhesion microcentrifuge tubes (Eppendorf). Reactions contained 1x HAT assay buffer (50mM Tris-HCl pH 7.5 (RT), 5% glycerol, 0.1mM EDTA, 50mM KCl), 1mM DTT, 10mM Na-Butyrate, 1x Complete EDTA protease inhibitor cocktail (Roche), 0.4U/ul murine RNase inhibitor (NEB), 0.1mg/ml BSA (NEB), 0-200nM H3 1-21 peptide (Anaspec) and the required concentration of RNA probe. 3 H labeled Acetyl Co-enzyme A ( 3 H-acetyl CoA) (specific activity = 3.95 Ci/mmol, 0.1uCi/ul, Perkin Elmer) was diluted in a 1:1 ratio with unlabeled acetyl CoA (Sigma) to give a final concentration of 100uM and 0.3uCi per reaction. 10nM of purified CBP-HAT domain construct was added to the reaction tubes at 20 s intervals and incubated at 30 C for 10 min to allow binding of RNA and H3 peptide substrate to reach equilibrium. The reaction was started at 20 s intervals by adding 3 H-acetyl CoA and run for exactly 10 min to estimate initial rate (Bowers et al., 2010) . After 10 min, reactions were quenched at 20 s intervals by pipetting half of the reaction mix (15ul) on to p81 Whatman paper (GE Healthcare). Reactions were dried at room temperature for 20 min, then paper was washed 3x 15 min in 50mM Sodium carbonate/bicarbonate pH9.3 before rinsing for 20 s in acetone and drying for 20 min at room temperature. The remaining half of the reaction was spotted on to p81 Whatman paper but not washed to determine the total radiation in each reaction, allowing calculation of acetylated peptide formation (uM product/s) (Berndsen and Denu, 2005) . Ultima Gold liquid scintillation fluid (Perkin Elmer) was added to the dried filter paper in scintilliation tubes, and incorporated 3 H-acetyl CoA (cpm) was counted using a liquid scintillation counter (Perkin Elmer). Background reaction controls were included containing all reaction components excluding the CBP-HAT domain construct and ± RNA to measure background labeling of peptide. Control reactions were also included with unlabeled acetyl CoA and RNA was purified using Trizol to ensure RNA integrity for the duration of the experiment ( Figure S5L ). Replicate experiments were fully cocktail (Roche)). Nuclei were pelleted by centrifugation at 2500rcf for 5 min, re-suspended in ChIP Buffer 2 (10mM Tris-HCl pH7.3 (RT), 200mM NaCl, 1mM EDTA, 0.5mM EGTA, 10mM Na-Butyrate, Complete protease inhibitor cocktail) and incubated with rotation for 10 min at room temperature. Nuclei were pelleted by centrifugation at 2500rcf for 5 min and re-suspended in ChIP lysis buffer 3 (10mM Tris-HCl pH8.0 (7.3@RT) 200mM NaCl 1mM EDTA 0.5mM EGTA 0.1% Na-deoxycholate 0.5% N-lauroylsarcosine, 0.1% SDS) for shearing. Chromatin was sheared to a 250-300bp average size using a Covaris S220, using 1ml millitubes and a high cell number shearing protocol for 15 min. Lysates were cleared by centrifugation at 20,000xg for 20 min. Concentration of lysates was determined by BCA assay, and IP's were done using equal concentrations (0.3-1.5mg) of sheared chromatin. Immunoprecipitations were performed by incubating with 2-4ug antibody overnight at 4 C with rotation. Immunocomplexes were recovered by adding blocked Protein A dynabeads for 1-2h and washed 5 times in ChIP wash buffer (50mM HEPES-KOH pH7.5, 500mM LiCl, 1mM EDTA, 1% NP40, 0.7% Na-deoxycholate, 0.1% N-lauroylsarcosine) and 1x in ChIP final wash buffer (10mM Tris-HCl pH8.0 (4 C), 1mM EDTA, 50mM NaCl). Immunocomplexes were eluted by incubating at 65 C for 30 min in ChIP elution buffer (50mM Tris-HCl pH8.0 (RT), 10mM EDTA, 1% SDS) and cross-linking was reversed by incubating overnight at 37 C. Immunoprecipitated DNA was treated with RNase A (0.2mg/ml final) for 2 hr at 37 C, then Proteinase K (0.2mg/ml final) for 2 hr at 55 C. DNA was then purified by phenol:chloroform extraction and ethanol precipitation and resuspended in 1x TE buffer. qPCR was carried out with Power SYBR (Applied Biosystems) using primers for target eRNA or control RNA sequences (Table S6) . PAR-CLIP RT-qPCR Cells were incubated for 16h with 150uM 4-thiouridine (4-SU). Plates were washed with PBS before cells were cross-linked using 400mJ/cm 2 365nM UV light with a Stratalinker UV crosslinker (Stratagene). Cleared cell lysates were prepared as for regular PAR-CLIP (see above). Immunopreciptations used equal concentrations (1-2mg per IP) of cleared cell lysate with a depleting amount of anti-GFP antibody (Abcam, ab290) for 2 hr at 4 C. 10% of cleared lysate was retained for input samples. Immunocomplexes were recovered for 30 min with BSA blocked Protein G dynabeads (ThermoFisher). Beads were collected and washed three times with CLIP wash buffer (as above) then IP50 buffer (as above), before resuspending in 1x Turbo DNase buffer. Contaminating DNA was removed by incubation with 2.5U Turbo DNase I for 30 min at 37 C. Beads were washed twice with CLIP wash buffer and IP50 buffer. Beads were resuspended in 1ml IP50 and transferred to a clean microcentrifuge tube for RNA purification. Proteinase K (20mg/ml, Roche) was diluted to 2mg/ml in Proteinase K (PK) buffer (50mM HEPES pH7.0, 50mM NaCl, 1mM EDTA, 1% SDS) and pre-incubated for 15 min at 37 C before use to remove contaminating RNase. Beads were collected and resupended in PK buffer mix (2mg/ml PK final), then incubated for 1h at 37 C to digest cross-linked protein. Immunopreciptated RNA and Input RNA was purified using acidic phenol:chloroform (ThermoFisher) and ethanol precipitation. RNA pellets were resuspended in 1x BTE buffer and used for Reverse transcription reactions using random primers with a High Capacity cDNA reverse transcription kit (Applied Biosystems). qPCR was carried out with Power SYBR (Applied Biosystems) using primers for target eRNA or control RNA sequences (Table S6) .
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical details of experiments are included in the Figures or Figure legends .
DATA AND SOFTWARE AVAILABILITY
Data Resources
The GEO repository series accession number for the CBP PAR-CLIP and background control (yeast Gal4-DBD and nls-GFP) PAR-CLIP datasets, as well as read density profiles for CBP-PAR-CLIP reported in this paper, is GEO: GSE75684 (http://www.ncbi.nlm. nih.gov/geo/query/acc.cgi?acc=GSE75684). Figure 1D , CBP PAR-CLIP required 4-SU: Top, Autoradiography; Bottom, western blot for CBP on PAR-CLIP membrane. Input was not 32 -P labeled, but resolved and transferred to the same membrane.
Supplemental Figures
(F and G) Whole autoradiography (F) and western blot (G) view of Figure 1E , CBP PAR-CLIP signal was sensitive to increasing RNase concentrations. 1x RNase cocktail contained: RNase A (0.01mU/ul) + RNase T1 (0.4mU/ul). (H) Example replicate autoradiography of Figure 1E , quantified in Figure 1F . 
